These findings, taken together with previous studies reporting that TRAF6 inhibition reduced osteoclast formation [19], demonstrate that inhibition of TRAF6 represents a promising approach to target not only MM cells but also their BM microenvironment. This evidence concerns the gene TRAF6 and Miyoshi myopathy.